Prospective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The aim of this study is to compare the efficacy of a thrice weekly 6-month regimen, 4S3H3R3Z3/2H3R3 (which consists of an initial 4 months of streptomycin (S), isoniazid (H), rifampicin (R), and pyrazinamide (Z) followed by 2 months of isoniazid and rifampicin), with a thrice weekly 9-month regimen, 4S3H3R3Z3/5H3R3 (which consists of an initial 4 months of streptomycin, isoniazid, rifampicin, and pyrazinamide followed by 5 months of isoniazid and rifampicin), in the treatment of cervical tuberculous lymphadenopathy. A total of 113 patients were recruited between August 1987 and December 1993. Twenty-two patients were excluded from the analysis because of defaulting treatment or modification of regimen. Ninety-one patients were included in the analysis. Forty-three patients were given the 6-month regimen, and 48 patients were given the 9-month regimen. Two (5%) patients of the 6-month regimen and one (2%) patient of the 9-month regimen had primary failure after completion of treatment (relative risk, 2.23; 95% confidence interval, 0.21 to 23.76). Of the 88 patients who had initial clinical remission after completion of treatment, the 5-year actuarial remission rates were 89% for the 6-month regimen and 90% for the 9-month regimen (Wilcoxon, p = 0.44). There were no significant differences of both primary failure rate and 5-year actuarial remission rate of the two regimens. The 6-month regimen is recommended as the initial treatment of tuberculous lymphadenopathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The 6-month recommendation is supported by studies that showed no difference between 6 and 9 months of treatment in cure rates (89%-94%) [45, 46] or relapse rates (3%) [47].”
From Current diagnosis and management of peripheral tuberculous lymphadenitis. (2011) · cites this paper as [46]
Citations
Cites
Mitchison, D. A., & Nunn, A. (1986) · PubMed · doi:10.1164/arrd.1986.133.3.423 · Cited by 291
Maldhure, B. R., Munje, R. P., Zodpey, S. P., Fuladi, A. B., & Pillai, A. (1997) · Lung India · Cited by 261
Efficacy of fine needle aspiration cytology in the diagnosis of tuberculous cervical lymphadenopathy
Lau, S. K., Wei, W. I., Hsu, C., & Engzell, U. C. G. (1990) · The Journal of Laryngology & Otology · doi:10.1017/s0022215100111697 · Cited by 176
Self-citationHong Kong Chest Service/British Medical Research Council (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/143.4_pt_1.700 · Cited by 163
Six months versus nine months chemotherapy for tuberculosis of lymph nodes: Final results
Campbell, I. A., Ormerod, L. P., Friend, J. A. R., Jenkins, P. A., & Prescott, R. J. (1993) · Respiratory Medicine · doi:10.1016/s0954-6111(05)80265-3 · Cited by 87
Hong Kong Chest Service/British Medical Research Council (1982) · Tubercle · doi:10.1016/s0041-3879(82)80044-5 · Cited by 83
Source of tubercle bacilli in cervical lymph nodes: A prospective study
Lau, S. K., Kwan, S., Lee, J., & Wei, W. I. (1991) · The Journal of Laryngology & Otology · doi:10.1017/s0022215100116603 · Cited by 66
Self-citationShort course chemotherapy for tuberculous lymphadenitis in children.
Jawahar, M. S., Sivasubramanian, S., Vijayan, V. K., Ramakrishnan, C. V., Paramasivan, C. N., Selvakumar, V, Paul, S., Tripathy, S. P., & Prabhakar, R. (1990) · BMJ · doi:10.1136/bmj.301.6748.359 · Cited by 64
Lau, S.-K., Wei, W. I., Kwan, S., & Yew, W.-W. (1991) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1991.01870130093023 · Cited by 57
Self-citationTuberculous cervical lymphadenopathy
Newcombe, J. F. (1971) · Postgraduate Medical Journal · doi:10.1136/pgmj.47.553.713 · Cited by 44
Cited by
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw376 · Cited by 1,170
Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J., & Dye, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14333-4 · Cited by 689
Current diagnosis and management of peripheral tuberculous lymphadenitis.
Fontanilla, J.-M., Barnes, A., & von Reyn, C. F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir454 · Cited by 299
“The 6-month recommendation is supported by studies that showed no difference between 6 and 9 months of treatment in cure rates (89%–94%) [45, 46] or relapse rates (3%) [47].”
BackgroundCervical tuberculous lymphadenopathy: changing clinical pattern and concepts in management
Jha, B. C., Dass, A., Nagarkar, N. M., Gupta, R., & Singhal, S. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.905.185 · Cited by 187
Metadata
- Authors
- YUEN, A., WONG, S., TAM, C., CHAN, S., WEI, W., & LAU, S.
- Affiliations
- Queen Mary Hospital (CN)
- ORCID
- WEI, W
- Venue
- Otolaryngology - Head and Neck Surgery
- Publisher
- Wiley
- Published
- 1997-02
- Volume
- 116
- Issue
- 2
- Pages
- 189-192
- ISSN
- 0161-6439 (ISSN-L)
- 0194-5998
- OpenAlex
- W1974353709
- Cited by
- 48
- References
- 19
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 5 · 2018: 4 · 2017: 1 · 2016: 1 · 2014: 1 · 2013: 2 · 2012: 1
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Otolaryngology (publishedVersion)
- PubMed (publishedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- PubMed
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Diagnosis and treatment of tuberculosis
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- tuberculosis chemotherapy, streptomycin, isoniazid, rifampicin, pyrazinamide, primary treatment failure, clinical remission, treatment duration
- MeSH terms
- Administration, Oral, Adult, Antibiotics, Antitubercular, Biopsy, Needle, Female, Humans, Injections, Intramuscular, Isoniazid, Male, Middle Aged, Mycobacterium tuberculosis, Neck, Prospective Studies, Retrospective Studies, Rifampin, Streptomycin, Tuberculosis, Lymph Node, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy. https://app.cochat.ai/papers/10.1016/s0194-5998(97)70323-1
- The paper
- YUEN, A., WONG, S., TAM, C., CHAN, S., WEI, W., & LAU, S. (1997). Prospective randomized study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy. Otolaryngology - Head and Neck Surgery. https://doi.org/10.1016/s0194-5998(97)70323-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.